CLAIMS

1. Use of an effective amount of an antibody and methotrexate in the manufacture of a medicament for a concurrent or sequential therapy for treating rheumatoid arthritis in a subject, wherein the antibody comprises the heavy chain variable region of sequence SEQ ID NO:2 and the light chain variable region of sequence SEQ ID NO:3, and the antibody is to be administered at between 100mg and 200 mg every two weeks and the methotrexate is to be administered at between 6mg and 25mg per week, and wherein the subject (1) was previously ineffectively treated for rheumatoid arthritis by administration of methotrexate and (2) was previously ineffectively treated for rheumatoid arthritis by administration of a TNF-α antagonist selected from the group consisting of etanercept, infliximab, adalimumab, golimumab and certolizumab pegol.

2. The use of claim 1, wherein the antibody is to be administered at 150 mg per two weeks or 200 mg per two weeks.

3. The use of claim 1 or 2, wherein the subject achieves a 20% improvement in the American College of Rheumatology core set disease index after 12 weeks of treatment.

4. The use of any of claims 1-3, wherein the subject achieves a 50% improvement in the American College of Rheumatology core set disease index after 12 weeks of treatment.

5. The use of any of claims 1-3, wherein the subject achieves a 70% improvement in the American College of Rheumatology core set disease index after 12 weeks of treatment.

6. The use of any of claims 1 to 5, wherein the subject has been treated with said anti-TNF-α antagonist for at least 3 months in the last 2 years or the subject was intolerant to at least one TNF-α antagonist.

7. The use of any of claims 1 to 6, wherein the antibody is sarilumab.

8. The use of any of claims 1 to 7, wherein the antibody is to be administered subcutaneously to the subject.